Since 2004, our highly qualified team has gained experience and expertise to conduct your entire research project under strong quality standards.
Cardiovascular disease remains the number 1 cause of death and disability worldwide with more than 17.5 million deaths in 2012, leading the cardiovascular therapeutic area to command the largest market for prescription drugs.
For example, the three main causes of mortality in Mauritians are Circulatory System diseases (31%), endocrine, nutritional and metabolic diseases (25.2 % mainly diabetes) and cancers (13.4%). Heart diseases correspond to 57% of the circulatory system diseases while cerebrovascular diseases account for 26.1 %.
CIDP helps its clients focus on developing cardiovascular and circulatory system therapies to improve patients’ lives in a variety of areas, including:
- coronary heart disease
- cerebrovascular disease
- peripheral arterial disease
- rheumatic heart disease
- congenital heart disease
- deep vein thrombosis and pulmonary embolism
Our centers are located in the new identified markets to offer you rapid enrollment during the peak seasons of the diseases.
CIDP has access to large groups of patients worldwide suffering from HIV/AIDS, Hepatitis (A, B & C), Chikungunya, Dingue, Influenza, to name a few.
In 2012, in the low-income countries, 4 out of the 10 leading causes of deaths, were due to infectious diseases (HIV, diarrheal disease, malaria & turberculosis). Worldwide, the infectious diseases were the 6th cause of death, mainly due to HIV/AIDS. India has the third largest HIV epidemic in the world with more than 2.1 million of people infected.
Mauritius and India have one of the highest rates of prevalence of diabetes mellitus in the world. Indeed in Mauritius, endocrine, nutritional and metabolic diseases are the second main cause of death with 25.2 % in 2013, among them 97.6 % due to Diabetes mellitus.
Recent data has shown than approximately 150 million people have diabetes mellitus worldwide with more than 90% corresponding to type 2 diabetes. This type is increasing due to new lifestyle. More people are getting overweight and inactive. In addition, the risk of developing type 2 diabetes is higher in certain ethnic groups especially those of Asian background. Looking at the statistic, the world health organization (WHO) fears that the number of people affected by the pathology may well double by the year 2025.
Through its subsidiary that enables a privilege access to patients and a network of very specialized investigators, CIDP has the capacity and the knowledge to accompany you for your clinical trial on endocrine, nutritional and metabolic diseases, including but not limited to diabetes, obesity and metabolic syndrome.
Nowadays, respiratory clinical research represents a new challenge as it represents more than 17 % of death each year. In 2012, three of the 10 leading causes of death were respiratory diseases: Chronic obstructive pulmonary disease-COPD (5.6%), lower respiratory infections (5.5%) and trachea bronchus/lung cancer (2.9%).
In 2013, more than 162 000 people died due to respiratory disease with 43.2% linked to pneumonia and 38.8% associated to COPD.
CIDP and its worldwide team of experts are ready to manage and monitor respiratory studies for various disease states, including:
- Acute and chronic sinusitis
- Allergic rhinitis (seasonal and perennial)
- Asthma (mild to severe)
- Chronic obstructive pulmonary disease (COPD)
- Cystic fibrosis
- Idiopathic pulmonary fibrosis
- Malignant neoplasm of trachea, bronchus and lung
- Other diseases of lung and respiratory system
Nowadays more than 7000 diseases are considered as rare as they affect at most five out of every 10,000 people. Even though these rare diseases are numerous and do not affect many people they are still of interest to research and large pharmaceutical company.
CIDP experts will accompany you in your new challenge and your research on Orphan diseases. Our worldwide network allows you to have the knowledge and the access to various orphan diseases such as Palmoplantar keratoderma (PPK), Lamellar ichthyosis, Acromegaly and multiple sclerosis.
Our pediatric study teams are experienced and bring specific considerations for the success of your pediatric clinical trials while maintaining the well-being of our patients. Our experts have the knowledge to design a unique approach for your studies, in using the validated tools and measurements needed to gather safety and efficacy data from pediatric patients.
We have managed and monitored several studies that use a variety of administration routes, including inhalants, sprays, shower gels, topical creams and ointments in various therapeutic areas including but not limited to dermatology, ophthalmology, metabolic diseases and internal medicine.
- Pigmentation disorders: Vitiligo, Melasma, Lentigo, PIHP
- Atopic dermatitis
- Seborrheic dermatitis
- Rare diseases e.g. KPP, Lamellar ichthyosis